DMT vs MDMA
A side-by-side research comparison of DMT and MDMA across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | DMT | MDMA |
|---|---|---|
| Full name | N,N-Dimethyltryptamine | 3,4-Methylenedioxymethamphetamine |
| Category | Psychedelics | Psychedelics |
| Status | Schedule I (research compound) | Schedule I (FDA Breakthrough Therapy for PTSD) |
| Mechanism | Activates serotonin 5-HT2A receptors, producing vivid changes in perception. When taken orally in ayahuasca, an MAO inhibitor is needed so it is not broken down too quickly. | Triggers large releases of serotonin (and to a lesser extent dopamine and norepinephrine) and increases oxytocin, prolactin and cortisol. This produces feelings of trust, openness and emotional closeness that support psychotherapy. |
| Molecular weight | 188.27 g/mol | 193.25 g/mol |
| Half-life | ~10-15 minutes | ~7-9 hours |
| Bioavailability | Inhaled/injected (very short); oral only with an MAO inhibitor | Oral, high |
| Typical dose | Controlled dosing in clinical studies | 75-125 mg (often with an optional supplemental half-dose) |
| Frequency | One to a few supervised sessions | A small number of monthly sessions |
| Route | Inhalation or IV in research; oral as ayahuasca | Oral, in a supervised therapeutic setting |
DMT reported benefits
- Studied for depression
- Very short experience aids research design
- Used to study consciousness
- Long traditional use as ayahuasca
MDMA reported benefits
- Studied for treatment-resistant PTSD
- Lowers fear response during trauma processing
- Increases trust and emotional openness
- Strong Phase 3 trial results from MAPS
Related comparisons
Research and educational reference only. Not medical advice.